Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page
Latest predictions
-
15.09.20
-
03.09.20
Your prediction

Novus Therapeutics Inc. Stock

A loss of -2.200% shows a downward development for Novus Therapeutics Inc..
The community is currently still undecided about Novus Therapeutics Inc. with 0 Buy predictions and 2 Sell predictions.

Pros and Cons of Novus Therapeutics Inc. in the next few years

Pros
?
Worthwhile Investment for the next years
?
Growth compared to competition
?
Non-cyclic/Cyclic
Cons
?
Conscious of the environment
?
Market Position
?
Brand
Tell us your opinion to access the 'Wisdom of the Crowds'
Register To Post

Other discussions about Novus Therapeutics Inc. Stock

New thread Forum

News

Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split: https://mms.businesswire.com/media/20191113005144/en/649046/5/NovusLogo-Color.jpg
Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split


Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its

Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences


Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune

Novus Therapeutics Announces Acquisition of Anelixis Therapeutics


Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company

Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced topline results

Novus Therapeutics Reports First Quarter 2020 Financial Results


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial